Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: July 20, 2015
Event: Filing of Post-Effective Amendment No. 2 to Form S-1 on Form S-3 with the SEC.
Key Financial Metrics
This filing is a regulatory update regarding securities registration and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the conversion of the Company's Registration Statement on Form S-1 (File No. 333-195385), originally declared effective on June 6, 2014, into a Registration Statement on Form S-3. This amendment includes updating revisions to ensure information is current as of the filing date.
Guidance, Outlook, and Unusual Items
Scope of Registration: The Post-Effective Amendment covers solely the resale of:
- 235,643 shares of common stock underlying warrants previously issued in private placement transactions.
- 15,401 shares of common stock issued upon the exercise of a portion of such warrants.
Background: These warrants are related to convertible notes issued by Nile Therapeutics, Inc., which converted following the merger between Nile and Capricor, Inc. (a wholly-owned subsidiary) on November 20, 2013.
Disclaimer: The report explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy the common stock.
Investor Verification Checklist
- Verify the status of the 235,643 shares underlying the warrants and the 15,401 shares issued upon exercise.
- Confirm the current market price and trading volume of Capricor Therapeutics common stock to assess potential dilution from the resale.
- Review the original Form S-1 (File No. 333-195385) to understand the full context of the Nile Therapeutics merger and warrant terms.
- Check for any subsequent filings regarding the actual sale of these shares under the new Form S-3 registration.